Development and validation of a prognostic immunoinflammatory index for patients with gastric cancer

Table 3 COX regression analysis of overall survival and progression-free survival

Parameter	OS				PFS
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value	HR (95%CI)	P value
Age (years)	2.035 (1.325-3.061)	0.001	1.541 (0.982-2.417)	0.051	1.978 (1.302-3.007)	0.001	1.488 (0.948-2.335)	0.084
Sex
Male	1 (Ref.)				1 (Ref.)
Female	0.912 (0.597-1.392)	0.669			0.918 (0.601-1.401)	0.692
Body mass index (kg/m2)	0.527 (0.342-0.811)	0.004	0.853 (0.536-1.357)	0.502	0.527 (0.342-0.812)	0.004	0.838 (0.526-1.334)	0.456
CD3(+) (%)	2.051 (1.387-3.033)	< 0.001			1.995 (1.350-2.949)	0.001
CD3(+)CD4(+) (%)	1.526 (0.961-2.424)	0.073			1.528 (0.963-2.426)	0.072
CD3(+)CD8(+) (%)	1.516 (1.034-2.221)	0.029			1.513 (1.003-2.217)	0.030
CD4(+)/CD8(+)	0523 (0.341-0.802)	0.002			0.517 (0.337-0.792)	0.002
CD3(+)CD4(+)CD8(+) (%)	1.516 (0.940-2.445)	0.088			1.504 (0.933-2.425)	0.094
CD19(+) (%)	0.351 (0.171-0.721)	0.003			0.358 (0.174-0.735)	0.004
CD3(-)CD16(+)CD56(+) (%)	0.703 (0.480-1.030)	0.070			0.712 (0.486-1.043)	0.082
CD3(+)CD16(+)CD56(+) (%)	1.880 (1.207-2.931)	0.005			1.865 (1.197-2.905)	0.005
PLR
< 2.81	1 (Ref.)				1 (Ref.)
≥ 2.81	1.913 (1.241-2.949)	0.003			1.898 (1.231-2.926)	0.003
NLR
< 115.22	1 (Ref.)				1 (Ref.)
≥ 155.22	2.390 (1.588)	< 0.001			2.338 (1.554-3.518)	< 0.001
SII
< 533.41	1 (Ref.)				1 (Ref.)
≥ 533.41	1.514 (1.035-2.217)	0.031			1.515 (1.035-2.217)	0.032
SIRI
< 1.51	1 (Ref.)				1 (Ref.)
≥ 1.51	1.899 (1.263-2.857)	0.002			1.881 (1.251-2.830)	0.002
Radical resection
Yes	1 (Ref.)		1 (Ref.)		1 (Ref.)		1 (Ref.)
No	4.356 (2.431-7.807)	< 0.001	1.909 (0.789-4.615)	0.151	4.182 (2.335-7.492)	< 0.001	1.513 (0.595-3.846)	0.384
Borrmann type
Ⅰ	1 (Ref.)		1 (Ref.)		1 (Ref.)		1 (Ref.)
Ⅱ	6.025 (1.435-25.300)	0.014	2.237 (0.477-10.497)	0.307	6.081 (1.448-25.533)	0.014	2.278 (0.484-10.729)	0.298
Ⅲ	8.012 (1.958-32.780)	0.004	2.350 (0.515-10.715)	0.270	8.088 (1.977-33.091)	0.004	2.435 (0.533-11.124)	0.251
Ⅳ	27.087 (6.171-118.891)	< 0.001	5.407 (1.063-27.496)	0.042	28.997 (6.605-127.294)	< 0.001	5.301 (1.043-26.930)	0.044
Lymph node positivity
No	1 (Ref.)		1 (Ref.)		1 (Ref.)		1 (Ref.)
Yes	3.445 (2.264-5.242)	< 0.001	1.132 (0.545-2.351)	0.740	3.537 (2.324-5.383)	< 0.001	1.010 (0.485-2.103)	0.979
Tumor size
< 20 mm	1 (Ref.)		1 (Ref.)		1 (Ref.)		1 (Ref.)
20–50 mm	2.710 (0.829-8.858)	0.099	0.708 (0.192-2.607)	0.603	2.715 (0.831-8.870)	0.098	0.686 (0.185-2.544)	0.573
> 50 mm	6.917 (2.176-21.988)	0.001	0.666 (0.178-2.494)	0.546	6.883 (2.165-21.878)	0.001	0.622 (0.164-2.361)	0.485
TNM stage
Ⅰ	1 (Ref.)		1 (Ref.)		1 (Ref.)		1 (Ref.)
Ⅱ	3.833 (1.585-7.910)	< 0.001	3.566 (1.545-8.233)	0.003	3.875 (1.878-7.996)	< 0.001	3.433 (1.475-7.989)	0.004
Ⅲ	11.441 (5.999-21.819)	< 0.001	9.085 (3.382-24.404)	< 0.001	11.807 (6.187-22.533)	< 0.001	8.541 (3.152-23.143)	< 0.001
Ⅳ	35.899 (15.895-81.079)	< 0.001	11.978 (3.812-37.641)	< 0.001	45.844 (20.022-104.969)	< 0.001	16.297 (4.934-53.825)	< 0.001
Carcinoembryonic antigen
< 1.97 ng/mL	1 (Ref.)		1 (Ref.)		1 (Ref.)		1 (Ref.)
≥ 1.97 ng/mL	1.586 (1.078-2.335)	0.019	1.425 (0.926-2.195)	0.107	1.543 (1.048-2.271)	0.028	1.328 (0.867-2.034)	0.192
CA199
< 10.19 U/L	1 (Ref.)				1 (Ref.)
≥ 10.19 U/L	1.355 (0.923-1.989)	0.120			1.347 (0.918-1.977)	0.128
CA724
< 2.17 U/L	1 (Ref.)		1 (Ref.)		1 (Ref.)		1 (Ref.)
≥ 2.17 U/L	2.159 (1.451-3.213)	< 0.001	1.510 (0.992-2.297)	0.054	2.154 (1.448-3.205)	< 0.001	1.456 (0.957-2.214)	0.079
CA125II
< 10.21 U/L	1 (Ref.)		1 (Ref.)		1 (Ref.)		1 (Ref.)
≥ 10.21 U/L	1.849 (1.250-2.734)	0.002	1.198 (0.791-1.813)	0.394	1.837 (1.242-2.716)	0.002	1.171 (0.770-1.781)	0.460
PII
< 70.69	1 (Ref.)		1 (Ref.)		1 (Ref.)		1 (Ref.)
≥ 70.69	1.888 (1.289-2.766)	0.001	1.670 (1.115-2.500)	0.013	1.881 (1.284-2.755)	0.001	1.639 (1.096-2.450)	0.016

CA125II: Carbohydrate antigen 125II; CA199: Carbohydrate antigen 199; CA724: Carbohydrate antigen 724; HR: Hazard ratio; NLR: Neutrophil-to-lymphocyte ratio; OS: Overall survival; PFS: Progression-free survival; PII: Prognostic immunoinflammatory index; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune inflammatory index; SIRI: Systemic inflammation response index; TNM: Tumor-node-metastasis.